{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:04:44Z","timestamp":1792677884248,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01353-4","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:09:10Z","timestamp":1761815350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease- A Growing Threat Beyond the Liver"],"prefix":"10.1007","volume":"27","author":[{"given":"Mohammad Dawar","family":"Zahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysha","family":"Almas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Parkash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"6","key":"1353_CR1","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-85.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1353_CR2","doi-asserted-by":"crossref","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.","DOI":"10.1186\/s12933-024-02434-5"},{"issue":"11","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","volume":"45","author":"L Nedkoff","year":"2023","unstructured":"Nedkoff L, Briffa T, Zemedikun D, Herrington S, Wright FL. Global trends in atherosclerotic cardiovascular disease. Clin Ther. 2023;45(11):1087\u201391.","journal-title":"Clin Ther"},{"issue":"4","key":"1353_CR4","first-page":"691","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702.","journal-title":"Gut"},{"key":"1353_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020163","author":"VA Ionescu","year":"2025","unstructured":"Ionescu VA, Gheorghe G, Bacalbasa N, Diaconu CC. Metabolic dysfunction-associated steatotic liver disease: pathogenetic links to cardiovascular risk. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15020163.","journal-title":"Biomolecules"},{"issue":"7","key":"1353_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11892-024-01542-6","volume":"24","author":"Y Castillo-N\u00fa\u00f1ez","year":"2024","unstructured":"Castillo-N\u00fa\u00f1ez Y, Almeda-Valdes P, Gonz\u00e1lez-G\u00e1lvez G, Arechavaleta-Granell MDR. Metabolic dysfunction-associated steatotic liver disease and atherosclerosis. Curr Diab Rep. 2024;24(7):158\u201366.","journal-title":"Curr Diab Rep"},{"key":"1353_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030324","author":"M Zisis","year":"2025","unstructured":"Zisis M, Chondrogianni ME, Androutsakos T, Rantos I, Oikonomou E, Chatzigeorgiou A, et al. Linking cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD): the role of cardiometabolic drugs in MASLD treatment. Biomolecules. 2025. https:\/\/doi.org\/10.3390\/biom15030324.","journal-title":"Biomolecules"},{"issue":"1","key":"1353_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-024-00187-4","volume":"10","author":"B Basil","year":"2024","unstructured":"Basil B, Myke-Mbata BK, Eze OE, Akubue AU. From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions. Clin Diabetes Endocrinol. 2024;10(1):39.","journal-title":"Clin Diabetes Endocrinol"},{"key":"1353_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","volume":"122","author":"A Mellemkj\u00e6r","year":"2024","unstructured":"Mellemkj\u00e6r A, Kj\u00e6r MB, Haldrup D, Gr\u00f8nb\u00e6k H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28\u201334.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1515\/mr-2021-0002","volume":"1","author":"CK Cheng","year":"2021","unstructured":"Cheng CK, Huang Y. The gut-cardiovascular connection: new era for cardiovascular therapy. Med Rev. 2021;1(1):23\u201346.","journal-title":"Med Rev"},{"issue":"1 & 2","key":"1353_CR11","first-page":"1","volume":"29","author":"H Yaghmaei","year":"2025","unstructured":"Yaghmaei H, Taromiha A, Nojoumi SA, Soltanipur M, Shahshenas S, Rezaei M, et al. Role of Gut-liver axis in non-alcoholic fatty liver disease. Iran Biomed J. 2025;29(1 & 2):1\u20138.","journal-title":"Iran Biomed J"},{"key":"1353_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073698","author":"J Maiuolo","year":"2022","unstructured":"Maiuolo J, Carresi C, Gliozzi M, Mollace R, Scarano F, Scicchitano M, et al. The contribution of gut microbiota and endothelial dysfunction in the development of arterial hypertension in animal models and in humans. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23073698.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1353_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.09.027","volume":"82","author":"Z Li","year":"2025","unstructured":"Li Z, Li Z, Cao D, Hu Y. Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world. J Hepatol. 2025;82(1):e29\u201331.","journal-title":"J Hepatol"},{"issue":"11","key":"1353_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"1353_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14188","volume":"54","author":"O De Filippo","year":"2024","unstructured":"De Filippo O, Di Pietro G, Nebiolo M, Ribaldone DG, Gatti M, Bruno F, et al. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: a meta-analysis. Eur J Clin Invest. 2024;54(9):e14188.","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"1353_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/hep4.1199","volume":"2","author":"D Kapuria","year":"2018","unstructured":"Kapuria D, Takyar VK, Etzion O, Surana P, O\u2019Keefe JH, Koh C. Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis. Hepatol Commun. 2018;2(8):877\u201387.","journal-title":"Hepatol Commun"},{"issue":"1","key":"1353_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.14423\/SMJ.0000000000001769","volume":"118","author":"N Nso","year":"2025","unstructured":"Nso N, Bookani KR, Trimingham M, Orji R, Njei B, Balasubramanian SS, et al. Liver fibrosis and cardiovascular events. South Med J. 2025;118(1):19\u201325.","journal-title":"South Med J"},{"issue":"1","key":"1353_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","volume":"59","author":"MC Ryan","year":"2013","unstructured":"Ryan MC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth S, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59(1):138\u201343.","journal-title":"J Hepatol"},{"issue":"3","key":"1353_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ajcnut.2024.07.015","volume":"120","author":"T Li","year":"2024","unstructured":"Li T, Zhao J, Cao H, Han X, Lu Y, Jiang F, et al. Dietary patterns in the progression of metabolic dysfunction-associated fatty liver disease to advanced liver disease: a prospective cohort study. Am J Clin Nutr. 2024;120(3):518\u201327.","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"1353_CR20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.dld.2022.12.013","volume":"55","author":"H Nam","year":"2023","unstructured":"Nam H, Yoo JJ, Cho Y, Kang SH, Ahn SB, Lee HW, et al. Effect of exercise-based interventions in nonalcoholic fatty liver disease: a systematic review with meta-analysis. Dig Liver Dis. 2023;55(9):1178\u201386.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1353_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11886-024-02185-5","volume":"27","author":"J Bernhard","year":"2025","unstructured":"Bernhard J, Galli L, Speidl WS, Krychtiuk KA. Cardiovascular risk reduction in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. Curr Cardiol Rep. 2025;27(1):28.","journal-title":"Curr Cardiol Rep"},{"key":"1353_CR22","doi-asserted-by":"crossref","unstructured":"Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916-22.","DOI":"10.1016\/S0140-6736(10)61272-X"},{"key":"1353_CR23","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-90","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"1353_CR24","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28","DOI":"10.1056\/NEJMoa1504720"},{"key":"1353_CR25","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-96","DOI":"10.1016\/S0140-6736(19)33041-7"},{"key":"1353_CR26","doi-asserted-by":"crossref","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919-28","DOI":"10.1038\/s41591-023-02603-1"},{"key":"1353_CR27","doi-asserted-by":"crossref","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021;385(17):1547-58","DOI":"10.1056\/NEJMoa2036205"},{"key":"1353_CR28","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"issue":"3","key":"1353_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s13142-015-0353-9","volume":"6","author":"JD Brown","year":"2016","unstructured":"Brown JD, Buscemi J, Milsom V, Malcolm R, O\u2019Neil PM. Effects on cardiovascular risk factors of weight losses limited to 5\u201310. Transl Behav Med. 2016;6(3):339\u201346.","journal-title":"Transl Behav Med"},{"issue":"5","key":"1353_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101363","volume":"7","author":"A Moolla","year":"2025","unstructured":"Moolla A, Poolman T, Othonos N, Dong J, Smith K, Cornfield T, et al. Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD. JHEP Reports. 2025;7(5):101363.","journal-title":"JHEP Reports"},{"key":"1353_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111891","volume":"217","author":"R Mollace","year":"2024","unstructured":"Mollace R, Longo S, Nardin M, Tavernese A, Musolino V, Cardamone A, et al. Role of MASLD in CVD: a review of emerging treatment options. Diabetes Res Clin Pract. 2024;217:111891.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"1353_CR32","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","volume":"22","author":"LA Abushamat","year":"2024","unstructured":"Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2024;22(8):1565\u201374.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1353_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/endocrines6020027","volume":"6","author":"R Choi","year":"2025","unstructured":"Choi R, Vemuri J, Poloju A, Raj R, Mehta A, Asgharpour A, et al. Current and emerging treatments for metabolic associated steatotic liver disease and diabetes: a narrative review. Endocrines. 2025;6(2):27.","journal-title":"Endocrines"},{"issue":"6","key":"1353_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84(6):729\u201335.","journal-title":"Drugs"},{"issue":"4","key":"1353_CR35","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"key":"1353_CR36","doi-asserted-by":"publisher","first-page":"1421386","DOI":"10.3389\/fnut.2024.1421386","volume":"11","author":"MJ Chen","year":"2024","unstructured":"Chen MJ, Chen Y, Lin JQ, Hu R, Liu D, Chen JY, et al. Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease. Front Nutr. 2024;11:1421386.","journal-title":"Front Nutr"},{"key":"1353_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1332870","volume":"12","author":"RG Kim","year":"2024","unstructured":"Kim RG, Ballantyne A, Conroy MB, Price JC, Inadomi JM. Screening for social determinants of health among populations at risk for MASLD: a scoping review. Front Public Health. 2024;12:1332870.","journal-title":"Front Public Health"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01353-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01353-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01353-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:09:23Z","timestamp":1761815363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01353-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01353-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}